President Trump’s Food and Drug Administration may not be as lax as the drug industry hoped. The agency rejected a debatably effective treatment for muscular dystrophy Wednesday, signaling that its self-professed openness to approving new drugs has limitations.
The drug, developed by PTC Therapeutics (PTCT), was meant to treat the rare disease Duchenne muscular dystrophy, but failed to differentiate itself from placebo in two clinical trials.
About the Author Reprints
